Should I buy or sell Can-Fite BioPharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CANF shares. View CANF analyst ratings or view top-rated stocks .

What is Can-Fite BioPharma's stock price target for 2024?

1 brokers have issued twelve-month price targets for Can-Fite BioPharma's stock. Their CANF share price targets range from $12.00 to $18.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 653.8% from the stock's current price. View analysts price targets for CANF or view top-rated stocks among Wall Street analysts .

How have CANF shares performed in 2024?

Can-Fite BioPharma's stock was trading at $2.20 at the start of the year. Since then, CANF shares have decreased by 9.5% and is now trading at $1.99. View the best growth stocks for 2024 here .

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSE:CANF) posted its quarterly earnings results on Thursday, March, 28th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.04. The company earned $0.16 million during the quarter, compared to the consensus estimate of $0.20 million. Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative trailing twelve-month return on equity of 113.75%.

When did Can-Fite BioPharma's stock split?

Shares of Can-Fite BioPharma reverse split on the morning of Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Can-Fite BioPharma?

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:CANF

Can-Fite BioPharma (CANF) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CANF Stock Alerts

$2.07

+0.10 (+5.08%)

(As of 11:30 AM ET)

Compare

Today's Range: $1.96
▼
$2.07
50-Day Range: $1.96
▼
$2.40
52-Week Range: $1.66
▼
$3.33

Volume: 1,878 shs
Average Volume: 19,705 shs
Market Capitalization: $7.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Get Can-Fite BioPharma alerts:

Can-Fite BioPharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 653.8% Upside
$15.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.42 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Can-Fite BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Can-Fite BioPharma has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for CANF.

0.0

Dividend Strength

Dividend Yield
Can-Fite BioPharma does not currently pay a dividend.
Dividend Growth
Can-Fite BioPharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CANF.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Can-Fite BioPharma this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Can-Fite BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.80% of the stock of Can-Fite BioPharma is held by insiders.
Percentage Held by Institutions
Only 21.00% of the stock of Can-Fite BioPharma is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Can-Fite BioPharma is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Can-Fite BioPharma is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Can-Fite BioPharma has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Can-Fite BioPharma Stock (NYSE:CANF)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

CANF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CANF Stock News Headlines

April 15, 2024 | businesswire.com

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

April 14, 2024 | americanbankingnews.com

Can-Fite BioPharma (NYSE:CANF) Now Covered by Analysts at StockNews.com

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 3, 2024 | businesswire.com

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

March 28, 2024 | finanznachrichten.de

Can-Fite BioPharma Ltd.: Can-Fite Reports 2023 Financial Results and Clinical Update

March 11, 2024 | businesswire.com

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

March 1, 2024 | investing.com

Can-Fite secures Canadian patent for liver disease drug

February 28, 2024 | businesswire.com

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 24, 2024 | wsj.com

Historical Prices

February 22, 2024 | finance.yahoo.com

Can-Fite BioPharma Ltd. (CANF)

February 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Can-Fite BioPharma Amidst Strategic Expansions and Positive Clinical Prospects

January 30, 2024 | investing.com

Can Fite Biopharma Ltd (CANF)

January 30, 2024 | investing.com

Can Fite Biopharma Ltd ADR (CANF)

January 30, 2024 | finance.yahoo.com

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

January 29, 2024 | finance.yahoo.com

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

December 20, 2023 | finance.yahoo.com

The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

December 18, 2023 | markets.businessinsider.com

Can-Fite Reports FDA Positive Response To Its Psoriasis Pediatric Plan - Quick Facts

December 18, 2023 | finance.yahoo.com

Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan

December 4, 2023 | finance.yahoo.com

Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

November 30, 2023 | finance.yahoo.com

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

November 21, 2023 | msn.com

Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today?

November 21, 2023 | finance.yahoo.com

Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

November 21, 2023 | finance.yahoo.com

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

November 1, 2023 | finance.yahoo.com

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

October 30, 2023 | finance.yahoo.com

Can-Fite Biopharma Ltd (CANF) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

October 30, 2023 | finance.yahoo.com

Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action

See More Headlines

Receive CANF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/28/2024
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:CANF
CUSIP: N/A
CIK: 1536196
Web: www.canfite.com
Phone: 972-3-924-1114
Fax: 972-3924-9378
Employees: 8
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $18.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +661.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,630,000.00
Net Margins: -1,027.46%
Pretax Margin: -1,027.46%
Return on Equity: -113.75%
Return on Assets: -69.91%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.91
Quick Ratio: 4.90

Sales & Book Value

Annual Sales: $740,000.00
Price / Sales: 9.42
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.76 per share
Price / Book: 1.12

Miscellaneous

Outstanding Shares: 3,540,000
Free Float: 3,512,000
Market Cap: $6.97 million
Optionable: Not Optionable
Beta: 1.53

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. Pnina Fishman Ph.D. (Age 76)
Founder, Chief Scientific Officer & Executive Chairperson
Comp: $644k
Mr. Motti Farbstein (Age 60)
CEO & Chief Operating and Financial Officer
Comp: $414k
Dr. Sari Fishman Ph.D. (Age 52)
Vice President of Business Development
Comp: $325k
Dr. Ilan Cohn Ph.D. (Age 70)
Co-Founder & Director
Dr. Stephen A. Harrison FACP
M.D., Member of Clinical Advisory Board & Consulting Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

Armistice Capital LLC
Bought 154,363 shares on 2/13/2024
Ownership: 4.361%

View All Institutional Transactions

CANF Stock Analysis - Frequently Asked Questions

Should I buy or sell Can-Fite BioPharma stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CANF shares.
View CANF analyst ratings or view top-rated stocks.
What is Can-Fite BioPharma's stock price target for 2024?: 1 brokers have issued twelve-month price targets for Can-Fite BioPharma's stock. Their CANF share price targets range from $12.00 to $18.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 653.8% from the stock's current price.
View analysts price targets for CANF or view top-rated stocks among Wall Street analysts.
How have CANF shares performed in 2024?: Can-Fite BioPharma's stock was trading at $2.20 at the start of the year. Since then, CANF shares have decreased by 9.5% and is now trading at $1.99.
View the best growth stocks for 2024 here.
How were Can-Fite BioPharma's earnings last quarter?: Can-Fite BioPharma Ltd. (NYSE:CANF) posted its quarterly earnings results on Thursday, March, 28th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.04. The company earned $0.16 million during the quarter, compared to the consensus estimate of $0.20 million. Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative trailing twelve-month return on equity of 113.75%.

When did Can-Fite BioPharma's stock split?: Shares of Can-Fite BioPharma reverse split on the morning of Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
How do I buy shares of Can-Fite BioPharma?: Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CANF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Can-Fite BioPharma (CANF) Stock Price, News & Analysis

Can-Fite BioPharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Can-Fite BioPharma Stock (NYSE:CANF)

CANF Stock Price History

CANF Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

CANF Stock Analysis - Frequently Asked Questions

Overall MarketRank^™